Drugs / BMS-986521
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07655518 | Jun → Dec 2026 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07655518 ↗ |
| Route | Oral | “oral administration of multiple doses of BMS-986521” NCT07655518 ↗ |